ANXA1 and inflammatory bowel disease: In fact, an in vivo proof of the study regarding ANXA1 proved that encapsulated targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated the recovery of intestinal inflammation in experimental IBD mice [81].